Efficacy in acute cinv. Medical search. Frequent questions

Patients indicate that among the most feared side effects of cancer are chemotherapy-induced nausea and vomiting (CINV), with up to 80% of patients affected if appropriate prophylaxis is not administered. (emjreviews.com)
Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy. (pillintrip.com)
Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy. (pillintrip.com)
Thirty to fifty percent of cancer patients undergoing chemotherapy will experience chemotherapy induced nausea and or vomiting (CINV) despite the use of antiemetic prophylaxis Uncontrollable CINV can lead to complications that add extra stress to patients, increase in healthcare costs, and utilization of resources. (asu.edu)

It has been 15 years since the 2008 approval by the Food and Drug Administration (FDA) of injectable Emend (fosaprepitant dimeglumine) as part of a three-day combination treatment regimen to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV) for patients who received highly emetogenic chemotherapy (HEC). (curetoday.com)
In 2016 single-dose injectable Emend, when combined with other drugs treating nausea and vomiting, was approved by the FDA to prevent delayed CINV in patients who'd received moderately emetogenic chemotherapy (MEC). (curetoday.com)
The cannabinoid extract (THC:CBD) was an appropriate adjuvant agent to reduce CINV in patients with gynecologic cancer who received high-emetogenic chemotherapy. (peoplebeatingcancer.org)
Palonosetron has been available internationally after being registered in the USA in 2003, and is indicated for the prevention of acute nausea and vomiting associated with highly emetogenic chemotherapy, and the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. (presseportal.ch)
The product has shown to be effective in preventing both acute and delayed CINV in patients receiving moderately emetogenic chemotherapy (MEC). (presseportal.ch)
There has been no phase III study of comparing the efficacy of first- and second-generation 5-HT 3 receptor antagonists in the triplet regimen with dexamethasone and aprepitant for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy (HEC). (medscape.com)
[ 8 ] In patients receiving moderately emetogenic chemotherapy (MEC), better CINV control was obtained with palonosetron than with a first-generation 5-HT 3 RA, [ 9 ] which supports current guideline recommendations for palonosetron use as a part of antiemetic premedication for MEC. (medscape.com)
Helsinn's NDA is supported by data from several clinical studies focused on the safety and pharmacokinetics of the drug in the prevention of CINV following highly emetogenic chemotherapy. (farmaindustriaticino.ch)
Akynzeo oral is indicated in the EU for adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy. (farmaindustriaticino.ch)
Akynzeo ® (netupitant 300mg/palonosetron 0.5mg) capsules for oral use was approved in October 2014 in the United States for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. (farmaindustriaticino.ch)

Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 Receptor Antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer, with a long half-life of 40 hours and at least 30 times higher receptor binding affinity than currently available compounds. (presseportal.ch)
Palonosetron demonstrates, in clinical trials and clinical practice, a unique long-lasting action in the prevention of CINV. (presseportal.ch)
The most commonly reported adverse reactions in CINV trials with palonosetron were headache (9 percent) and constipation (5 percent), and they were similar to the comparators. (presseportal.ch)
Palonosetron, marketed as Aloxi®, is the leading brand in the USA within the CINV Day of Chemo segment, and it is steadily growing in the European markets. (presseportal.ch)
Aprepitant, a neurokinin-1 (NK-1) receptor antagonist, and palonosetron, a second-generation 5-HT 3 RA, are two recently introduced antiemetic agents expected to improve control of CINV. (medscape.com)
In this paper, we will report the results of randomized phase III study to evaluate the efficacy of palonosetron versus granisetron in the standard triplet antiemetic therapy for cisplatin-based HEC. (medscape.com)
Palonosetron, a 5HT 3 inhibitor, prevents nausea and vomiting during the acute phase and netupitant, an NK-1 inhibitor, prevents nausea and vomiting during both the acute and delayed phases after cancer chemotherapy. (farmaindustriaticino.ch)

An oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as IV use against delayed CINV. (wikipedia.org)
Unlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking," Sun Yat-Sen University researchers wrote in the JAMA Network Open study, which they posited was to their knowledge, "the first study to assess the efficacy and safety of fosaprepitant during combined radiotherapy-HEC. (curetoday.com)
The efficacy of amifostine in the prevention of oral mucositis should be evaluated in new, well-designed, sufficiently powered, randomized, controlled trials," they concluded. (cancertherapyadvisor.com)

MATTERHORN is a phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of roxadustat in anemia of lower risk-MDS. (bvsalud.org)
Patient to the sib, coffey c, liang y, placebo-controlled phase of acute drug interactions in dogs. (myjuicecup.com)

Comparison of the efficacy of olanzapine, metoclopramide and domperidone for the symptom abolishment of chemotherapy induced breakthrough nausea and vomiting (CINV): a randomized clinical trial. (edu.in)
Chemotherapy-induced nausea and vomiting (CINV) is one of the most difficult short-term side effects resulting from undergoing all types of chemo regimens. (peoplebeatingcancer.org)
Despite the usefulness and efficacy of chemotherapy , it is still associated with numerous side effects, especially chemotherapy-induced nausea and vomiting (CINV). (peoplebeatingcancer.org)
The NCCN, MASCC/ESMO, and ASCO guidelines include management recommendations for both chemotherapy-induced nausea and vomiting (CINV) and radiation-induced nausea and vomiting (RINV). (medscape.com)
Adherence, antiemetics, cancer, chemotherapy-induced nausea and vomiting (CINV), guidelines. (emjreviews.com)
Chemotherapy-induced nausea and vomiting (CINV) is a non-hematologic toxicity of chemotherapy that severely impairs the quality of life of patients and reduces their treatment compliance. (medscape.com)
Olanzapine (Zyprexa), an FDA-approved antipsychotic, effectively controlled chemotherapy-induced nausea and vomiting (CINV) in patients who failed to respond to guideline-recommended antiemetic therapy in a phase III trial presented at the ASCO Annual Meeting. (ascopost.com)

Although the use of antiemetic agents have improved, CINV remains an issue with most patients. (peoplebeatingcancer.org)

Clinical trials suggest that it is more effective than other 5-HT3 antagonists in preventing delayed CINV (nausea and vomiting that occur more than 24 hours after the first dose of chemotherapy). (wikipedia.org)
their clinical efficacy on lower urinary tract symptoms was demonstrated in the Cannabinoids in Multiple Sclerosis study. (desertharvest.com)

But its efficacy for mucositis in cancer patients has been mixed and controversial, the authors reported. (cancertherapyadvisor.com)
Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. (viho.es)

The primary efficacy endpoint of the OL phase was the proportion of patients with transfusion independence (TI) for ≥ 8 consecutive weeks in the first 28 treatment weeks. (bvsalud.org)
A secondary efficacy endpoint was the proportion of patients with a ≥ 50% reduction in RBC transfusions over an 8-week period compared with baseline. (bvsalud.org)
In my experience as both a cancer survivor and cancer coach, CINV is a common side effect of all chemo regimens for all cancer types- not just gynecologic cancer patients. (peoplebeatingcancer.org)
CINV is one of the most common adverse effects and leads to significant morbidity and deterioration of patients' quality of life. (peoplebeatingcancer.org)
Australians can now access a new drug to prevent acute (and delayed phase) nausea and vomiting which may occur in cancer patients undergoing chemotherapy1. (presseportal.ch)
Amifostine reduces the incidence of acute and late radiotherapy-associated xerostomia among patients with head and neck cancer , for example. (cancertherapyadvisor.com)
Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. (trodelvyhcp.com)
Although the first-generation BTK inhibitor ibrutinib has shown significant efficacy in the treatment of patients with CLL, it is associated with notable cardiac toxicity, including cardiac arrhythmias, cardiac failure, and sudden death. (oncnursingnews.com)

Randomized controlled studies have shown that the addition of aprepitant to dexamethasone and a 5-HT 3 RA can achieve better CINV control when compared with the doublet antiemetic therapy. (medscape.com)
Systemic therapy is often used in conjunction with other modalities that constitute local therapy (i.e., treatments whose efficacy is confined to the anatomic area where they are applied) for cancer such as radiation therapy, surgery or hyperthermia therapy. (worldsbest.rehab)
Hot and cold therapy: Apply a cold pack to the affected area for 20 minutes several times a day during the initial acute stage to reduce inflammation. (kurrajongnaturalmedicinecentre.com.au)

Methods: Elementary school personnel in Southern Arizona were asked to do an online pre-survey to evaluate knowledge and self-efficacy, view a short presentation on cystic fibrosis, and complete a post-survey. (asu.edu)

Optimal management of CINV and other treatment-related side effects has been associated with improved quality of life, longer duration of anticancer treatments, and decreased utilisation of emergency care. (emjreviews.com)
CINV can lead to chemotherapy dose reductions, treatment delays, chemotherapy changes, or discontinuation of treatment. (asu.edu)

I think it is important to point out the antiemetics and CBD oil can be used together to combat CINV. (peoplebeatingcancer.org)

The concomitant administration of a NK1 receptor antagonist, such as aprepitant, significantly increases the efficacy of 5-HT3 antagonists in preventing both acute and delayed CINV. (wikipedia.org)

CINV affects patient quality of life, may interfere with chemotherapy compliance which can possibly influence cancer survival outcomes, and results in greater healthcare resource utilisation. (emjreviews.com)
it affects quality of life and reduces social and economic efficacy [1]. (kurrajongnaturalmedicinecentre.com.au)

This review set out to identify the initiatives needed to achieve better cancer-induced nausea and vomiting (CINV) control worldwide. (emjreviews.com)

It is an isoquinoline derivative, and is effective in preventing delayed CINV. (wikipedia.org)

evidence for efficacy is limited but promising for chronic pain management. (phase-iv.com)

Efficacy of contraceptives may be reduced during administration of and for 28 days following the last dose of EMEND. (nih.gov)

Although they are more effective at controlling CINV-where they stop symptoms altogether in up to 70% of people, and reduce them in the remaining 30%-, they are just as effective as other agents for PONV. (wikipedia.org)

Aim: The purpose of this project was to determine if educating elementary school personnel would improve their knowledge and self-efficacy in caring for students with Cystic Fibrosis (CF) and improve the health and educational outcomes of students with this disease. (asu.edu)
Synthesis of evidence indicated that an online CF educational intervention would improve knowledge and self-efficacy among school personnel, thereby improving the health and educational outcomes of students with CF. (asu.edu)

Results: Analysis showed a statistically significant improvement in perceived knowledge (p = .024) and self-efficacy scores (p = .034). (asu.edu)

it is therefore significantly more effective for delayed CINV. (wikipedia.org)

The 5-HT 3 receptor antagonists have been shown to be effective in preventing chemotherapy-induced nausea and vomiting (CINV), and now 1 of the newest agents in this field, palonosetron ( Aloxi , Onicil , Paloxi ), marketed by Helsinn Healthcare, has shown superior efficacy to a second-generation agent, granisetron ( Kytril , Roche). (medscape.com)
Japanese researchers reported here at the 33rd European Society for Medical Oncology Congress that palonosetron was superior to granisetron in preventing delayed-phase CINV. (medscape.com)
Palonosetron is a highly selective second-generation 5-HT 3 receptor antagonist that has demonstrated efficacy and long-lasting protection from CINV. (medscape.com)
In this study, Dr. Yoshizawa and colleagues from the PALO Japanese Cooperative Study Group compared the efficacy of single-dose IV palonosetron (0.75 mg) with IV granisetron (40 µg/kg) in 1114 patients who were scheduled to receive at least 50 mg/m 2 of cisplatin or of epirubicin or doxorubicin plus cyclophosphamide (AC/EC). (medscape.com)
Subgroup analyses by sex, age, and chemotherapy protocol showed similar results: palonosetron was similar to granisetron in preventing acute-phase CINV but superior in eliciting an overall complete response and preventing delayed-phase CINV. (medscape.com)
We compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSLC) receiving cisplatin-based high emetogenic chemotherapy (HEC). (researchsquare.com)
There was no significant difference between granisetron and palonosetron in both acute and delayed control of emesis in NSCLC patients receiving cisplatin-based HEC. (researchsquare.com)
Because of this interaction, it is thought that palonosetron may be more beneficial, especially in the treatment of delayed CINV. (researchsquare.com)
Studies have shown that palonosetron is superior to first-generation 5-HT3RAs in preventing both acute and delayed CINV when given alone, and only delayed CINV when given in combination with dexamethasone. (researchsquare.com)
[ 6 - 12 ] Palonosetron was statistically significantly more effective in preventing delayed CINV only in the TRIPLE study of Suzuki et al. (researchsquare.com)
This study compared the efficacy and tolerability of palonosetron, a novel, second-generation 5-HT 3 receptor antagonist, with ondansetron. (elsevierpure.com)
0.01) for palonosetron 0.25 mg than ondansetron during the acute (0-24 h) (81.0% versus 68.6%, respectively, delayed (24-120 h) (74.1 % versus 55.1 %) and overall (0-120 h) (69.3% versus 50.3%) periods. (elsevierpure.com)
Conclusions: A single i.v. dose of palonosetron 0.25 mg was significantly superior to i.v. ondansetron 32 mg in the prevention of acute and delayed CINV. (elsevierpure.com)
2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. (nih.gov)
3. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron? (nih.gov)
Recent studies suggest that the second generation 5-HT3 receptor antagonist palonosetron and neurokinin-1 receptor antagonist aprepitant may have some efficacy in controlling delayed CINV compared to the first generation 5-HT3 receptor antagonists. (kjco.org)
Here we evaluated the efficacy and toxicity of a combination of aprepitant, palonosetron, and dexamethasone as antiemetic prophylaxis in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy, and examined the potential of aprepitant to affect the pharmacokinetics of ifosfamide, which is primarily metabolized by CYP3A4. (springer.com)
This study showed that aprepitant in combination with palonosetron and dexamethasone was safe and effectively controlled CINV in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy. (springer.com)
Single-agent comparison trials suggested that the newer agent palonosetron offers superior control of CINV, said Dr. Gralla. (themedicalxchange.com)
Lugano, Switzerland, April 24, 2018 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announced it will be presenting a poster on the budget impact for payers of fixed combination netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV), at the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2018 in Boston, MA, 23 - 26April 2018. (helsinn.com)
AKYNZEO ® (netupitant 300mg/palonosetron 0.5mg) capsules was approved in October 2014 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. (helsinn.com)
AKYNZEO ® (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. (helsinn.com)
AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT 3 ) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. (helsinn.com)
Lugano, Switzerland April 20, 2018 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO ® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. (helsinn.com)
AKYNZEO ® is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. (helsinn.com)
AKYNZEO (netupitant/palonosetron) capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. (akynzeo.com)

It has a higher binding affinity and longer half-life than other 5-HT 3 receptor antagonists, and in the United States has been approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy. (medscape.com)
Clinical trials suggest that it is more effective than other 5-HT3 antagonists in preventing delayed CINV (nausea and vomiting that occur more than 24 hours after the first dose of chemotherapy). (wikipedia.org)
Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect decreasing quality of life in patients with cancer. (nih.gov)
The main cause of chemotherapy-induced nausea and vomiting (CINV) is thought that serotonin, substance P, and dopamine released due to the damage in the gastrointestinal system caused by chemotherapy stimulate 5-HT3 (5 hydroxytryptamine 3), NK-1 (neurokinin-1), and dopamine receptors in target organs, respectively. (researchsquare.com)
In clinical trials, single intravenous or oral doses of dolasetron were effective in preventing acute chemotherapy-induced nausea and vomiting (CINV). (nih.gov)
Dolasetron has also shown efficacy in preventing radiotherapy-induced nausea and vomiting (RINV) in preliminary studies. (nih.gov)
Background: Although all first-generation 5-HT 3 receptor antagonists demonstrate efficacy in preventing acute chemotherapy-induced nausea and vomiting (CINV), effective prevention of delayed CINV has not yet been achieved. (elsevierpure.com)
8. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. (nih.gov)
13. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. (nih.gov)
17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. (nih.gov)
Ginger has also been studied outcomes included acute prevalence of CINV, acute and for its efficacy for acute chemotherapy-induced nausea and delayed severity of CINV, and assessment of blinding. (pharmapdf.com)
the prevalence of delayed nausea or vomiting, prevalence of Materials and methods We performed a randomized, acute CINV, or severity of delayed vomiting or acute double-blind, placebo-controlled trial in 162 patients with nausea and vomiting. (pharmapdf.com)
Participants who took both ginger and cancer who were receiving chemotherapy and had experi- aprepitant had more severe acute nausea than participants enced CINV during at least one previous round of who took only aprepitant. (pharmapdf.com)
Aprepitant, a selective neurokinin-1 receptor antagonist approved for prevention of chemotherapy-induced nausea and vomiting (CINV), is an inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, which is involved in the clearance of several chemotherapeutic agents. (springer.com)
Data on nausea, vomiting, and use of rescue medication were collected, and the primary efficacy end point was the proportion of patients with complete response (CR), defined as no vomiting and no use of rescue therapy during 120 h after initiation of chemotherapy. (springer.com)
Milan - Dramatic progress has occurred over the past three decades in the management of chemotherapy-induced nausea and vomiting (CINV). (themedicalxchange.com)
Clinicians should set higher goals for controlling chemotherapy-induced nausea and vomiting (CINV), said Richard Gralla, MD, Professor of Medicine, North Shore-LIJ, Hofstra University, Lake Success, NY, at the ESMO Congress this year. (themedicalxchange.com)
Perception and reality were in accord for acute nausea and vomiting. (themedicalxchange.com)
Postoperative nausea and vomiting (PONV) represents a significant market opportunity in the acute care setting that leverages our existing sales organization. (herontx.com)
Despite guidelines and medications available for the management of chemotherapy-induced nausea and vomiting (CINV), many patients with cancer are persistently affected by this dreadful adverse effect. (ajmc.com)
Chemotherapy-induced nausea and vomiting (CINV) is among the most common and distressing adverse events (AEs) associated with chemotherapy. (ajmc.com)
6-11 While nausea and vomiting, and the resulting effects, are the main influencers of HRQOL, drivers of the financial burden of CINV include direct costs resulting from inadequate prophylaxis, indirect costs from diminished HRQOL, and the cost of noncompliance with cancer therapy such as disease progression due to CINV. (ajmc.com)
14 Factors affecting CINV include a history of nausea and vomiting (eg, motion sickness), age, sex, alcohol consumption, type and dosage of chemotherapeutic agent, administration route, and/or schedule. (ajmc.com)
Chemotherapeutic agents have been classified according to the associated risk of inducing acute nausea and vomiting as high-emetic risk chemotherapeutic (HEC) agents, moderate-emetic risk chemotherapeutic (MEC) agents, and low-emetic risk (LER) chemotherapeutic agents. (ajmc.com)
Although nausea was better controlled than vomiting, late-phase response was not as well controlled as acute-phase response. (ajmc.com)
Based on the high efficacy of gel on emesis induced by cisplatin, and its high bioavailability, transdermal ondansetron gel could be a promising convenient system to prevent nausea and vomiting following administration of antineoplastic drugs. (innovareacademics.in)
It is a primary drug utilized to treat, prohibit and stop chemotherapy-induced nausea and vomiting (CINV), it is also efficient in prevailing postoperative nausea and vomiting (PONV) and after radiation therapy-induced nausea and vomiting [6-8]. (innovareacademics.in)
The FDA has approved AKYNZEO ® IV in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. (helsinn.com)
Oral AKYNZEO ® was previously approved by the FDA as a fixed combination oral agent in 2014 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. (helsinn.com)
[ 2 ] However, it is less well appreciated that there can also be long-term consequences from the medications that are used for management of treatment-emergent acute symptoms, such as nausea, anxiety, and insomnia. (medscape.com)
Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy. (pillintrip.com)
Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy. (pillintrip.com)
5-HT3 receptor antagonist and has antinausea and, antiemetic properties used mostly for chemotherapy-, induced nausea and vomiting (CINV). (ericlowitt.com)
Zuplenz® is marketed in the US for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) and has a target market of $4.6bn by 2018. (traderpower.com)

The concomitant administration of a NK1 receptor antagonist, such as aprepitant, significantly increases the efficacy of 5-HT3 antagonists in preventing both acute and delayed CINV. (wikipedia.org)
There was also a significant decrease in both acute and delayed CINV with NK-1 inhibitor drugs such as aprepitant. (researchsquare.com)

Acute myeloid leukemia (AML) is distinguished by an uncontrolled proliferation of myeloid blasts within the bloodstream, bone marrow, and possibly other tissues. (marksmanhealthcare.com)
Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, is being tested in combination with cytarabine in the international phase III MIRROS clinical trial (NCT02545283) to see if omprove the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML). (oncnursingnews.com)
Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia. (onclive.com)

2 A significant decrease in acute CINV was achieved with first-generation 5-HT3 receptor antagonists (5-HT3RA) such as ondansetron, granisetron, and tropisetron. (researchsquare.com)
9. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies. (nih.gov)
16. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. (nih.gov)
Combined use of granisetron and dexamathasone provide more complete and prolonged protection against acute stage CINV, but limited effect against delayed CINV. (kjco.org)
Antipsychotic drug olanzapine showed improved effect against CINV when additionally used with dexamethasone and granisetron. (kjco.org)

A second necessary step towards eliminating CINV is the optimal use of available antiemetic agents, particularly from the three major classes: corticosteroids, serotonin 5-HT 3 antagonists, and substance P/neurokinin 1 (NK 1 ) receptor antagonists. (themedicalxchange.com)
56% of patients in the study were not even administered antiemetic medication for delayed-onset CINV. (ajmc.com)
Currently the combination treatment of antiemetic medicines with different mechanisms of actions are recommended for the prevention of CINV. (helsinn.com)
The approval of AKYNZEO ® in IV formulation will offer to US patients and healthcare providers an alternative route of administration of the only fixed antiemetic combination targeting two distinct CINV pathways in a single dose. (helsinn.com)

Recent updates of guidelines have increased emphasis on use of NK1 antagonists as an essential component of strategies to prevent and control CINV in cancer patients. (themedicalxchange.com)
The analysis examined randomized clinical trials comparing control of acute emesis with 5-HT 3 antagonists alone, or in combination with dexamethasone. (themedicalxchange.com)

It is known that first-generation 5HT3RAs have similar efficacy when used alone or in combination with dexamethasone. (researchsquare.com)

It is an isoquinoline derivative, and is effective in preventing delayed CINV. (wikipedia.org)

However, both agents demonstrated similar efficacy in preventing acute-phase CINV. (medscape.com)

The results showed no significant difference in the rate of complete response or control of acute and delayed emesis," Dr. Gralla explained. (themedicalxchange.com)

However, its efficacy for delayed CINV Main results There were no differences between groups in in a diverse oncology population is unknown. (pharmapdf.com)

Although they have significant curative effects on acute CINV, they are not effective enough on delayed CINV. (researchsquare.com)

Addressing our client's interest in understanding the efficacy and safety of the available narcolepsy medications, and the impact in patient's quality of life and other outcomes, we conducted a comprehensive analysis, extracting data from 150 articles using a predefined grid for this project. (marksmanhealthcare.com)

Secondary end points included efficacy in treatment of delayed CINV (≤5 days post-chemotherapy) and overall tolerability. (elsevierpure.com)

Acute toxicity of SF-SBM was evaluated in Wistar rats by administering a single oral dose of 2000 mg/kg of SF-SBM. (bvsalud.org)

Cisplatin was classified as the highest emetic risk group as it causes acute and delayed vomiting [19, 20]. (innovareacademics.in)

[ 1 ] Stimulation of 5-HT3 receptors by serotonin is considered the most critical pathway for acute phase CINV, while stimulation of NK-1 receptors with substance P is considered the most important pathway for delayed phase CINV. (researchsquare.com)

Agents that Individuals 18 years and older who had a histologically could safely further decrease the rates of CINV, and confirmed diagnosis of cancer currently being treated with especially delayed CINV, are needed. (pharmapdf.com)

Acute vomiting refers to symptoms that occur within 24 hours of the administration of chemotherapy. (medscape.com)

Although they are more effective at controlling CINV-where they stop symptoms altogether in up to 70% of people, and reduce them in the remaining 30%-, they are just as effective as other agents for PONV. (wikipedia.org)

The nephroprotective efficacy of SF-SBM was further assessed at low (LD), medium (MD) and high (HD) doses of 32.1, 64.2, and 128.4 mg/kg, respectively, administered orally. (bvsalud.org)

Being an acute leukemia, AML is characterized by rapid progression, and if left untreated, is typically fatal within weeks or months. (marksmanhealthcare.com)

12,13 The initial incidence of CINV is predictive for CINV in subsequent cycles, and a lack of control of CINV in the acute phase is often predictive of an inability to control delayed CINV. (ajmc.com)

The primary end-point of the assessment was the total control rates of CINV in the acute and delayed phases after chemotherapy. (nih.gov)

After the logistic regression analysis with adjustment for other known covariates, the total control rate was significantly higher in the 3435TT genotype group during the acute phase (p = 0.021). (nih.gov)

The quality of the information offered and the lively dis- cussion led to adoption of recommendations which regulators consider important in assuring the quality, safety and efficacy of medicines. (who.int)
We are dedicated to providing exceptional pharmaceutical products to ensure efficacy and safety. (tetrabiopharma.com)

10:1) reduction in CINV event-related medical costs, relative to virtually no change in pharmacy costs. (helsinn.com)

Anatomy1

Organisms6

Diseases14

Chemicals and Drugs63

Analytical, Diagnostic and Therapeutic Techniques and Equipment49

Psychiatry and Psychology2

Phenomena and Processes12

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena1

Technology, Industry, Agriculture2

Humanities1

Information Science1

Health Care24

Prophylaxis4

Emetogenic10

Palonosetron7

Prevention3

Placebo-controlled2

Chemotherapy induced7

Antiemetic agents1

Clinical2

Mucositis2

Patients8

Therapy3

Evaluate1

Treatment2

Antiemetics1

Receptor1

Affects2

Cancer1

Derivative1

Management1

Days1

Reduce1

Improve2

Significant1

Effective1

Palonosetron26

Nausea34

Aprepitant2

Myeloid leukemia3

Granisetron5

Antiemetic4

Antagonists2

Dexamethasone1

Preventing delayed1

Similar efficacy1

Emesis1

Oncology1

Curative1

Outcomes1

Tolerability1

Toxicity1

Emetic risk1

Delayed-phase1

Decrease1

Occur1

Symptoms1

Doses1

Progression1

Subsequent1

Assessment1

Control1

Safety2

Reduction1